Do analysts recommend SYNT or SCPA?

Synthomer presently has a consensus price target of GBX 118.75, indicating a potential upside of 3.62%. Given Synthomer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Synthomer is more favorable than Scapa Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synthomer 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Scapa Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, SYNT or ZTF?

Zotefoams has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Zotefoams, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthomer £1.80B 0.10 -£82.04M -£73.60 N/A Zotefoams £176.29M 1.27 £9.80M £50.29 9.05

Is SYNT or ZTF more profitable?

Zotefoams has a net margin of 13.88% compared to Synthomer's net margin of -6.81%. Zotefoams' return on equity of 18.18% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Synthomer -6.81% -13.27% -0.28% Zotefoams 13.88% 18.18% 5.48%

Which has higher valuation & earnings, SYNT or TET?

Treatt has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthomer £1.80B 0.10 -£82.04M -£73.60 N/A Treatt £128.29M 1.40 £11.22M £7.22 42.24

Is SYNT or TET more profitable?

Treatt has a net margin of 3.40% compared to Synthomer's net margin of -6.81%. Treatt's return on equity of 3.22% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Synthomer -6.81% -13.27% -0.28% Treatt 3.40% 3.22% 6.72%

Do analysts rate SYNT or HDD?

Synthomer currently has a consensus target price of GBX 118.75, indicating a potential upside of 3.62%. Given Synthomer's stronger consensus rating and higher possible upside, research analysts plainly believe Synthomer is more favorable than Hardide. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synthomer 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Hardide 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, SYNT or HDD?

Hardide has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Hardide, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthomer £1.80B 0.10 -£82.04M -£73.60 N/A Hardide £8.02M 12.87 -£1.89M £1.80 72.72

Is SYNT or HDD more profitable?

Hardide has a net margin of 15.60% compared to Synthomer's net margin of -6.81%. Hardide's return on equity of 32.49% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Synthomer -6.81% -13.27% -0.28% Hardide 15.60% 32.49% -9.80%

Which has preferable earnings and valuation, SYNT or IOF?

Iofina has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Iofina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthomer £1.80B 0.10 -£82.04M -£73.60 N/A Iofina £68.69M 1.34 £4.28M £4.50 10.67

Is SYNT or IOF more profitable?

Iofina has a net margin of 12.91% compared to Synthomer's net margin of -6.81%. Iofina's return on equity of 15.30% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Synthomer -6.81% -13.27% -0.28% Iofina 12.91% 15.30% 5.18%

Synthomer (SYNT) Competitors

GBX 114.73 +0.13 (+0.11%)

As of 12:31 PM Eastern

Compare

SYNT vs. SCPA, ZTF, TET, HDD, and IOF

Should you buy Synthomer stock or one of its competitors? Synthomer's main competitors and comparable companies include Scapa Group (SCPA), Zotefoams (ZTF), Treatt (TET), Hardide (HDD), and Iofina (IOF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "specialty chemicals" industry.

How does Synthomer compare to Scapa Group?

Synthomer (LON:SYNT) and Scapa Group (LON:SCPA) are both small-cap materials companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Scapa Group has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Scapa Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.80B	0.10	-£82.04M	-£73.60	N/A
Scapa Group	£281.80M	0.00	N/A	-£29.30	N/A

In the previous week, Synthomer's average media sentiment score of 0.00 equaled Scapa Group'saverage media sentiment score.

Company	Overall Sentiment
Synthomer	Neutral
Scapa Group	Neutral

Synthomer presently has a consensus price target of GBX 118.75, indicating a potential upside of 3.62%. Given Synthomer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Synthomer is more favorable than Scapa Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Scapa Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.9% of Synthomer shares are held by institutional investors. 5.0% of Synthomer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scapa Group has a net margin of 0.00% compared to Synthomer's net margin of -6.81%. Scapa Group's return on equity of 0.00% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-6.81%	-13.27%	-0.28%
Scapa Group	N/A	N/A	N/A

Summary

Synthomer beats Scapa Group on 7 of the 11 factors compared between the two stocks.

How does Synthomer compare to Zotefoams?

Synthomer (LON:SYNT) and Zotefoams (LON:ZTF) are both small-cap materials companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

In the previous week, Zotefoams had 4 more articles in the media than Synthomer. MarketBeat recorded 4 mentions for Zotefoams and 0 mentions for Synthomer. Zotefoams' average media sentiment score of 0.89 beat Synthomer's score of 0.00 indicating that Zotefoams is being referred to more favorably in the news media.

Company	Overall Sentiment
Synthomer	Neutral
Zotefoams	Positive

Zotefoams has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Zotefoams, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.80B	0.10	-£82.04M	-£73.60	N/A
Zotefoams	£176.29M	1.27	£9.80M	£50.29	9.05

Synthomer has a beta of 0.998, meaning that its share price is 0% less volatile than the broader market. Comparatively, Zotefoams has a beta of 1.238, meaning that its share price is 24% more volatile than the broader market.

14.9% of Synthomer shares are held by institutional investors. Comparatively, 28.8% of Zotefoams shares are held by institutional investors. 5.0% of Synthomer shares are held by insiders. Comparatively, 4.5% of Zotefoams shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zotefoams has a net margin of 13.88% compared to Synthomer's net margin of -6.81%. Zotefoams' return on equity of 18.18% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-6.81%	-13.27%	-0.28%
Zotefoams	13.88%	18.18%	5.48%

Synthomer presently has a consensus price target of GBX 118.75, indicating a potential upside of 3.62%. Zotefoams has a consensus price target of GBX 605, indicating a potential upside of 32.97%. Given Zotefoams' stronger consensus rating and higher possible upside, analysts clearly believe Zotefoams is more favorable than Synthomer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zotefoams	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Zotefoams beats Synthomer on 14 of the 16 factors compared between the two stocks.

How does Synthomer compare to Treatt?

Synthomer (LON:SYNT) and Treatt (LON:TET) are both small-cap materials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

14.9% of Synthomer shares are held by institutional investors. Comparatively, 17.5% of Treatt shares are held by institutional investors. 5.0% of Synthomer shares are held by company insiders. Comparatively, 4.1% of Treatt shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Treatt has a net margin of 3.40% compared to Synthomer's net margin of -6.81%. Treatt's return on equity of 3.22% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-6.81%	-13.27%	-0.28%
Treatt	3.40%	3.22%	6.72%

Synthomer presently has a consensus price target of GBX 118.75, suggesting a potential upside of 3.62%. Treatt has a consensus price target of GBX 242.50, suggesting a potential downside of 20.49%. Given Synthomer's higher probable upside, research analysts plainly believe Synthomer is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Treatt	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Synthomer's average media sentiment score of 0.00 equaled Treatt'saverage media sentiment score.

Company	Overall Sentiment
Synthomer	Neutral
Treatt	Neutral

Synthomer has a beta of 0.998, indicating that its share price is 0% less volatile than the broader market. Comparatively, Treatt has a beta of 0.907, indicating that its share price is 9% less volatile than the broader market.

Treatt has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.80B	0.10	-£82.04M	-£73.60	N/A
Treatt	£128.29M	1.40	£11.22M	£7.22	42.24

Summary

Treatt beats Synthomer on 9 of the 13 factors compared between the two stocks.

How does Synthomer compare to Hardide?

Synthomer (LON:SYNT) and Hardide (LON:HDD) are both small-cap materials companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Synthomer has a beta of 0.998, meaning that its share price is 0% less volatile than the broader market. Comparatively, Hardide has a beta of 1.146, meaning that its share price is 15% more volatile than the broader market.

Synthomer currently has a consensus target price of GBX 118.75, indicating a potential upside of 3.62%. Given Synthomer's stronger consensus rating and higher possible upside, research analysts plainly believe Synthomer is more favorable than Hardide.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hardide	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hardide has a net margin of 15.60% compared to Synthomer's net margin of -6.81%. Hardide's return on equity of 32.49% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-6.81%	-13.27%	-0.28%
Hardide	15.60%	32.49%	-9.80%

Hardide has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Hardide, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.80B	0.10	-£82.04M	-£73.60	N/A
Hardide	£8.02M	12.87	-£1.89M	£1.80	72.72

In the previous week, Hardide had 2 more articles in the media than Synthomer. MarketBeat recorded 2 mentions for Hardide and 0 mentions for Synthomer. Hardide's average media sentiment score of 0.28 beat Synthomer's score of 0.00 indicating that Hardide is being referred to more favorably in the news media.

Company	Overall Sentiment
Synthomer	Neutral
Hardide	Neutral

14.9% of Synthomer shares are owned by institutional investors. Comparatively, 11.4% of Hardide shares are owned by institutional investors. 5.0% of Synthomer shares are owned by insiders. Comparatively, 65.7% of Hardide shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Hardide beats Synthomer on 10 of the 16 factors compared between the two stocks.

How does Synthomer compare to Iofina?

Synthomer (LON:SYNT) and Iofina (LON:IOF) are both small-cap materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

14.9% of Synthomer shares are held by institutional investors. Comparatively, 1.3% of Iofina shares are held by institutional investors. 5.0% of Synthomer shares are held by company insiders. Comparatively, 13.4% of Iofina shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Synthomer has a beta of 0.998, meaning that its share price is 0% less volatile than the broader market. Comparatively, Iofina has a beta of 0.965, meaning that its share price is 4% less volatile than the broader market.

Iofina has a net margin of 12.91% compared to Synthomer's net margin of -6.81%. Iofina's return on equity of 15.30% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-6.81%	-13.27%	-0.28%
Iofina	12.91%	15.30%	5.18%

Iofina has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Iofina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.80B	0.10	-£82.04M	-£73.60	N/A
Iofina	£68.69M	1.34	£4.28M	£4.50	10.67

Synthomer presently has a consensus target price of GBX 118.75, suggesting a potential upside of 3.62%. Iofina has a consensus target price of GBX 70, suggesting a potential upside of 45.83%. Given Iofina's stronger consensus rating and higher probable upside, analysts clearly believe Iofina is more favorable than Synthomer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Iofina	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Synthomer's average media sentiment score of 0.00 equaled Iofina'saverage media sentiment score.

Company	Overall Sentiment
Synthomer	Neutral
Iofina	Neutral

Summary

Iofina beats Synthomer on 10 of the 13 factors compared between the two stocks.

Get Synthomer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYNT vs. The Competition

Export

Metric	Synthomer	Chemicals Industry	Materials Sector	LON Exchange
Market Cap	£187.88M	£11.48B	£4.67B	£2.85B
Dividend Yield	28.47%	2.97%	4.30%	5.10%
P/E Ratio	-1.56	31.62	27.17	23.39
Price / Sales	0.10	2.41	5.91	5.03
Price / Cash	2.28	14.81	20.89	20.23
Price / Book	0.17	3.44	4.11	2.52
Net Income	-£82.04M	£235.78M	£159.56M	£5.88B
7 Day Performance	5.26%	-0.03%	-0.59%	-0.12%
1 Month Performance	5.25%	-1.09%	-6.81%	-1.95%
1 Year Performance	112.46%	11.42%	6.80%	6.86%

Synthomer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYNT Synthomer	0.39 of 5 stars	GBX 114.73 +0.1%	GBX 118.75 +3.5%	+135.8%	£187.88M	£1.80B	N/A	4,200
SCPA Scapa Group	N/A	N/A	N/A	N/A	£402.98M	£281.80M	N/A	1,461
ZTF Zotefoams	4.7655 of 5 stars	GBX 452 -5.4%	GBX 605 +33.8%	+21.7%	£222.85M	£176.29M	8.99	549	News Coverage Analyst Forecast Insider Trade High Trading Volume
TET Treatt	N/A	GBX 305 flat	GBX 242.50 -20.5%	N/A	£180.06M	£128.29M	42.24	350
HDD Hardide	N/A	GBX 133.30 +2.5%	N/A	+1,736.2%	£105.06M	£8.02M	74.06	46

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SYNT) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synthomer (SYNT) Competitors

SYNT vs. SCPA, ZTF, TET, HDD, and IOF

How does Synthomer compare to Scapa Group?

Summary

How does Synthomer compare to Zotefoams?

Summary

How does Synthomer compare to Treatt?

Summary

How does Synthomer compare to Hardide?

Summary

How does Synthomer compare to Iofina?

Summary

Media Sentiment Over Time

SYNT vs. The Competition

Synthomer Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synthomer (SYNT) Competitors

SYNT vs. SCPA, ZTF, TET, HDD, and IOF

How does Synthomer compare to Scapa Group?

Which has stronger valuation and earnings, SYNT or SCPA?

Does the media refer more to SYNT or SCPA?

Do analysts recommend SYNT or SCPA?

Do institutionals and insiders have more ownership in SYNT or SCPA?

Is SYNT or SCPA more profitable?

Summary

How does Synthomer compare to Zotefoams?

Does the media favor SYNT or ZTF?

Which has stronger valuation and earnings, SYNT or ZTF?

Which has more risk and volatility, SYNT or ZTF?

Do institutionals and insiders have more ownership in SYNT or ZTF?

Is SYNT or ZTF more profitable?

Do analysts recommend SYNT or ZTF?

Summary

How does Synthomer compare to Treatt?

Do institutionals and insiders hold more shares of SYNT or TET?

Is SYNT or TET more profitable?

Do analysts rate SYNT or TET?

Does the media prefer SYNT or TET?

Which has more risk & volatility, SYNT or TET?

Which has higher valuation & earnings, SYNT or TET?

Summary

How does Synthomer compare to Hardide?

Which has more volatility and risk, SYNT or HDD?

Do analysts rate SYNT or HDD?

Is SYNT or HDD more profitable?

Which has preferable valuation and earnings, SYNT or HDD?

Does the media refer more to SYNT or HDD?

Do insiders & institutionals have more ownership in SYNT or HDD?

Summary

How does Synthomer compare to Iofina?

Do institutionals and insiders believe in SYNT or IOF?

Which has more volatility and risk, SYNT or IOF?

Is SYNT or IOF more profitable?

Which has preferable earnings and valuation, SYNT or IOF?

Do analysts rate SYNT or IOF?

Does the media refer more to SYNT or IOF?

Summary

Media Sentiment Over Time

SYNT vs. The Competition

Synthomer Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools